Vanta Bioscience Ltd

Vanta Bioscience Ltd's Board of Directors approved the audited standalone and consolidated financial results for the half year and financial year ended March 31, 2026. Mr. Dopesh Raja Mulakala has been re-appointed as Managing Director for another 3 years effective April 18, 2026, subject to shareholder approval. The statutory auditors, M/s Mathesh & Ramana, issued an unmodified opinion on the financial results. For FY26, Vanta Bioscience reported total revenue of ₹167.41 Lacs and a net profit of ₹1.81 Lacs.

Vanta Bioscience Ltd's board approved audited standalone and consolidated financial results for the half year and financial year ended March 31, 2026. Mr. Dopesh Raja Mulakala has been re-appointed as Managing Director for another 3 years effective April 18, 2026, subject to shareholder approval. The statutory auditors, M/s Mathesh & Ramana, issued an unmodified opinion on the financial results. The meeting was held on May 30, 2026, from 6:00 PM to 7:00 PM.

Vanta Bioscience Ltd has scheduled a Board of Directors meeting on May 30, 2026, to consider and approve the Standalone and Consolidated Audited Financial Results for the half year and financial year ended March 31, 2026. The board will also review the Audit Reports issued by the Statutory Auditors. The Trading Window remains closed from April 01, 2026, until June 1, 2026, for designated persons as per the Insider Trading Policy.

Vanta Bioscience Ltd has announced the closure of its trading window for all designated persons, their immediate relatives, and all other concerned persons. This closure is in accordance with the Company’s Code of Conduct for Prohibition of Insider Trading and the SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will remain closed from Wednesday, April 01, 2026 till the expiry of 48 hours after the declaration of the Audited Financial Results of the Company for the half year and year ended March 31, 2026. The date of the board meeting for consideration and declaration of the Audited Financial Results will be intimated in due course.

Vanta Bioscience Ltd has clarified that it has disclosed all material information to BSE Ltd, as required by the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company is not aware of any reason for significant movement in the price of its shares, stating that the movement is market-driven and not connected to the company's management. The company reiterates its commitment to adhere to all compliances under the Listing Regulations and other applicable laws.

Vanta Bioscience Ltd has reported its financial results for the half year ended September 30, 2025. The company's net loss decreased compared to the same period last year. The company's standalone and consolidated financial results were approved by the board of directors in a meeting held on November 14, 2025. The review report was issued by Mathesh & Ramana Chartered Accountants.

Vanta Bioscience Ltd. announced the unaudited standalone and consolidated financial results for the half year ended September 30, 2025. The standalone financial results show a revenue from operation of 30.18 Lakhs, total revenues of 36.57 Lakhs, and a net profit after tax of (0.57) Lakhs. The consolidated financial results include the interim financial statements of a subsidiary with total assets of 393.75 Lakhs, total revenues of Nil, total net profit after tax of (0.57) Lakhs, and cash flows (net outflow) of Nil for the period from April 1, 2025 to September 30, 2025. The Board of Directors approved these results in a meeting held on November 14, 2025.

Vanta Bioscience Ltd has scheduled a Board of Directors meeting on November 14, 2025, to consider and approve the Unaudited financial results for the half year ended September 30, 2025. The meeting will also take note of the limited review report of the statutory auditors. The trading window for all designated persons under the Insider Trading Policy of the Company is closed from October 01, 2025, till November 16, 2025 (both days inclusive).

Vanta Bioscience Ltd has released its annual report for the financial year 2024-25. The report, which includes the Notice of the 9th AGM, was sent to members within the stipulated time but inadvertently missed uploading on the Listing Centre. It is now available on the company's website. The report includes the Corporate Information, Board's Report, Management Discussion and Analysis Report, Independent Auditor's Report on Standalone Financial Statements, Standalone Balance Sheet, Standalone Statement of Profit and Loss, Standalone Cash Flows Statement, Notes to the Standalone Financial Statements, Independent Auditors' Report on Consolidated Financial Statements, Consolidated Balance Sheet, Consolidated Statement of Profit and Loss, Consolidated Cash Flows Statement, Notes to the Consolidated Financial Statements, Attendance Slip, Proxy Form, Route Map, and other relevant details.

Vanta Bioscience Ltd. has announced the closure of its trading window for all designated persons, their immediate relatives, and all concerned. The closure is in accordance with the company's Code of Conduct for Prohibition of Insider Trading and the SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will be closed from Wednesday, October 1, 2025, till 48 hours after the declaration of unaudited financial results for the half year ended September 30, 2025. The date of the Board of Directors' meeting to approve the unaudited financial results will be intimated in due course.